SCHEMBL25368705

SCHEMBL25368705

CS(=O)(=O)Nc1cc(Br)cc([N+](=O)[O-])c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 1/20 0.54
KDM4E B2RXH2 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
CYP19A1 P11511 10/20 0.43
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
TSHR P16473 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
MAPT P10636 2/20 0.39
PTGS1 P23219 2/20 0.39
PTGS2 P35354 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MLNR O43193 1/20 0.39
LMNA P02545 1/20 0.39
MMP1 P03956 1/20 0.39
MPO P05164 1/20 0.39
GLA P06280 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15220185 0.88 KDM4E (0.51) KDM4ETDP1CYP19A1MEN1KMT2A
SCHEMBL11641924 0.88 KDM4E (0.51) KDM4ETDP1CYP19A1MEN1KMT2A
SCHEMBL2872188 0.81 TSHR (0.57) KDM4ETDP1CYP19A1MEN1KMT2A
SCHEMBL25352438 0.80 KDM4E (0.46) KDM4ETDP1CYP19A1MEN1KMT2A
SCHEMBL31561144 0.80 KDM4E (0.46) KDM4ETDP1CYP19A1MEN1KMT2A
SCHEMBL24270146 0.79 ALDH1A1 (0.52) ACP1KDM4ECYP19A1MEN1KMT2A
SCHEMBL3912636 0.78 LMNA (0.52) KDM4ETDP1CYP19A1MEN1KMT2A
SCHEMBL711594 0.76 KDM4E (0.52) KDM4ETDP1MEN1KMT2AMAPT
SCHEMBL1120932 0.76 SMN1; SMN2 (0.53) KDM4ETDP1MEN1KMT2ACYP3A4
SCHEMBL2875965 0.76 KIF11 (0.47) KDM4ETDP1CYP19A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 US disclosed
EP-4479380-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 EP disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B ACP1 4305/4885KDM4E 1934/4885TDP1 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.